Key result
Pixantrone was shown to be superior to other single-agent therapies for the salvage treatment of relapsed or refractory aggressive non-Hodgkin lymphoma.
Why the study?
Does pixantrone improve outcomes compared to other single-agent therapies in patients with relapsed or refractory aggressive non-Hodgkin lymphoma?
Does pixantrone improve outcomes compared to other single-agent therapies in patients with relapsed or refractory aggressive non-Hodgkin lymphoma?
Pixantrone offers a superior salvage treatment option for relapsed/refractory aggressive non-Hodgkin lymphoma with the potential for reduced cardiotoxicity compared to traditional anthracyclines.
May support pixantrone in relapsed/refractory aggressive NHL salvage; Level 5 evidence leaves open need for randomized confirmation.
IMPORTANCE OF THE FIELD: At present there is no standard treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma who progress following second-line therapy. Anthracyclines are highly active drugs, but their use in this setting is limited by cumulative cardiac toxicity. Pixantrone is a new aza-anthracenedione structurally similar to mitoxantrone and anthracyclines. This compound has been developed to minimize cardiac toxicity without reducing efficacy. AREAS COVERED IN THIS REVIEW: This review summarizes the preclinical and clinical trial data for the use of pixantrone for the treatment of aggressive non-Hodgkin lymphoma. WHAT THE READER WILL GAIN: An overview of the mechanism of action of pixantrone, preclinical data, clinical efficacy, safety data and future developments for this compound. TAKE HOME MESSAGE: Pixantrone has been shown to be superior to other single-agent therapies for the salvage treatment of relapsed/refractory aggressive non-Hodgkin lymphoma. The pixantrone application will be submitted to the regulatory authorities in the USA and in Europe.
No takes yet. Share an insight, caveat, or question.
Mukherji et al. (2010) conducted a review in relapsed or refractory aggressive non-Hodgkin lymphoma. Pixantrone vs. other single-agent therapies was evaluated. Pixantrone was shown to be superior to other single-agent therapies for the salvage treatment of relapsed or refractory aggressive non-Hodgkin lymphoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: